PROJECTS AND INITIATIVES
Grants
Funded projects led by IMPACT members, partnering with other members as co-PI or co-I.
American Cancer Society TheoryLab Collaborative Grant 2021
Understanding estrogen-driven breast tumorigenesis in invasive lobular carcinoma.
Co-PIs: Matt Sikora, Julie Ostrander
CDMRP Breast Cancer Research Program: Breakthrough Award Level 1, Partnering PIs
Estrogen-driven breast tumorigenesis in invasive lobular carcinoma.
Co-PIs: Matt Sikora, Julie Ostrander
W81XWH-22-1-0715; 7/2022 - 7/2025
American Cancer Society Research Scholar Grant
Selective Antagonists of Mutant Estrogen Receptors.
PI: Terry Moore
Co-I: Sean Fanning
RSG-21-037-01; 7/2021 - 6/2025
CDMRP Peer Reviewed Cancer Research Program: Translational Team Science Award
Progestin Therapy for Endometrial Cancer
PI: Jay Gertz
Co-I: Christy Hagan
HT9425-23-1-0745; 6/2023 - 5/2027
National Cancer Institute "Basic Mechanisms in Health Disparities" R01
Elucidating a novel WNT4 regulatory axis as a driver of gynecologic cancer health disparities.
PI: Matt Sikora
Co-I: Lindsey Treviño
R01CA285446; 9/2023 - 8/2028
https://reporter.nih.gov/search/w9owgGklyE6kevZLJo0OSg/project-details/10773991
Meetings and Proceedings
Steroid Hormones and Receptors in Health and Disease: A Research Conference Co-Organized by FASEB and the International Committee on Rapid Responses to Steroid Hormones (RRSH).
IMPACT Meeting Chairs | Zeynep Madak-Erdogan, Dan Frigo
IMPACT Invited Speakers | Matt Sikora, Doug Kojetin, Becca Riggins, Erik Nelson;
IMPACT Session Chairs | Sayee Anakk, Jay Gertz, Christy Hagan, Kristy Brown, Subhamoy Dasgupta, Lindsey Trevino
Barton M, Frigo DE, Madak-Erdogan Z, Mauvais-Jarvis F, Prossnitz ER. | May 25-27, 2021. FASEB J. 2021 Nov;35(11):e21858. | doi: 10.1096/fj.202101228. Access the paper.
ASBMB Annual Meeting 2021 - Signaling Interest Group — Nuclear Receptors
IMPACT Symposia Chairs | Becca Riggins, Doug Kojetin
IMPACT Invited Speakers | Dan Gorelick, Sreejith Nair
https://www.asbmb.org/meetings-events/2021-annual-meeting/networking
Publications and Collaborative Research
Papers co-authored by IMPACT members or associated with IMPACT membership collaboration
WNT4 regulates cellular metabolism via intracellular activity at the mitochondria in breast and gynecologic cancers.
Sottnik JL, Shackleford MT, Villagomez FR, Bahnassy S, Oesterreich S, Hu J, Madak-Erdogan M, Riggins RB, Corr BR, Cook LS, Treviño LS, Bitler BG, Sikora MJ. | bioRxiv 2022.07.15.499747; doi:10.1101/2022.07.15.499747. In press, Cancer Research Communications . Access the paper.
In Situ Spatial Reconstruction of Distinct Normal and Pathological Cell Populations Within the Human Adrenal Gland.
Fu R, Walters K, Kaufman ML, Koc K, Baldwin A, Clay MR, Basham KJ, Kiseljak-Vassiliades K, Fishbein L, Mukherjee N. | J Endocr Soc. 2023 Oct 25;7(12):bvad131. doi: 10.1210/jendso/bvad131. Access the paper.
Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer.
Blanchard Z, Rush CM, Arnesen S, Vahrenkamp JM, Rodriguez AC, Jarboe EA, Brown C, Chang MEK, Flory MR, Mohammed H, Modzelewska K, Lum DH, Gertz J. | Mol Cancer Res. 2023 Jun 26. pii: MCR-22-0848. doi: 10.1158/1541-7786.MCR-22-0848. Access the paper.
Alternative activation.
Young K, Fanning S. | Elife. 2023 Jun 12;12. pii: e89112. doi: 10.7554/eLife.89112. Access the paper.
Senescence-induced immune remodeling facilitates metastatic adrenal cancer in a sex-dimorphic manner.
Warde KM, Smith LJ, Liu L, Stubben CJ, Lohman BK, Willett PW, Ammer JL, Castaneda-Hernandez G, Imodoye SO, Zhang C, Jones KD, Converso-Baran K, Ekiz HA, Barry M, Clay MR, Kiseljak-Vassiliades K, Giordano TJ, Hammer GD, Basham KJ. | Nat Aging. 2023 Jul;3(7):846-865. doi: 10.1038/s43587-023-00420-2. Access the paper.
Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate Cancer.
Hahn AW, Siddiqui BA, Leo J, Dondossola E, Basham KJ, Miranti CK, Frigo DE. | Endocrinology. 2023 Apr 17;164(6). pii: bqad078. doi: 10.1210/endocr/bqad078. Access the paper.
Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer.
Leo J, Dondossola E, Basham KJ, Wilson NR, Alhalabi O, Gao J, Kurnit KC, White MG, McQuade JL, Westin SN, Wellberg EA, Frigo DE. | Endocrinology. 2023 Apr 17;164(6). pii: bqad071. doi: 10.1210/endocr/bqad071. Access the paper.
Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line.
Rush CM, Blanchard Z, Polaski JT, Osborne KS, Osby K, Vahrenkamp JM, Yang CH, Lum DH, Hagan CR, Leslie KK, Pufall MA, Thiel KW, Gertz J. | Sci Rep. 2022 Nov 17;12(1):19731. doi: 10.1038/s41598-022-24211-8. Access the paper.
The nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancer.
Nelczyk AT, Ma L, Gupta AD, Gamage HEV, McHenry MT, Henn MA, Kadiri M, Wang Y, Krawczynska N, Bendre S, He S, Shahoei SH, Madak-Erdogan Z, Hsiao SH, Saleh T, Carpenter V, Gewirtz DA, Spinella MJ, Nelson ER. | Biochim Biophys Acta Mol Basis Dis. 2022 Nov 1;1868(11):166515. doi: 10.1016/j.bbadis.2022.166515. Access the paper.
Labeling of a mutant estrogen receptor with an Affimer in a breast cancer cell line.
Ren P, Tiede C, Fanning SW, Adams T, Speirs V, Nelson ER, Cheng C, Moore TW, Greene GL, Tomlinson D, Selvin PR. | Biophys J. 2022 Oct 4;121(19):3651-3662. doi: 10.1016/j.bpj.2022.06.028. Access the paper.
Steroid Hormones and Receptors in Health and Disease: A Research Conference Co-Organized by FASEB and the International Committee on Rapid Responses to Steroid Hormones (RRSH), May 25-27, 2021
Barton M, Frigo DE, Madak-Erdogan Z, Mauvais-Jarvis F, Prossnitz ER. | FASEB J. 2021 Nov;35(11):e21858. doi: 10.1096/fj.202101228. Access the paper.
WNT4 regulates cellular metabolism via intracellular activity at the mitochondria in breast and gynecologic cancers.
Sottnik JL, Shackleford MT, Villagomez FR, Bahnassy S, Oesterreich S, Hu J, Madak-Erdogan Z, Riggins RB, Corr BR, Cook LS, Treviño LS, Bitler BG, Sikora MJ. | bioRxiv 2022.07.15.499747. | doi: https://doi.org/10.1101/2022.07.15.499747. Access the paper.
Endocrine-Disrupting Chemicals and Breast Cancer: Disparities in Exposure and Importance of Research Inclusivity.
Santaliz Casiano A, Lee A, Teteh D, Madak Erdogan Z, Treviño L. | Endocrinology. 2022 May 1;163(5):bqac034. | doi: 10.1210/endocr/bqac034. PMID: 35325096. Access the paper.
Unlocking the Mysteries of Lobular Breast Cancer Biology Needs the Right Combination of Preclinical Models.
Bahnassy S, Sikora MJ, Riggins RB. | Mol Cancer Res. 2022 Mar 11:molcanres.0018.2022. | doi: 10.1158/1541-7786.MCR-22-0018. Epub ahead of print. PMID: 35276005. Access the paper.
TLX, an Orphan Nuclear Receptor With Emerging Roles in Physiology and Disease.
Nelson AT, Wang Y, Nelson ER. | Endocrinology. 2021 Nov 1;162(11):bqab184. | doi: 10.1210/endocr/bqab184. Access the paper.
The Interface of Nuclear and Membrane Steroid Signaling.
Treviño LS, Gorelick DA. | Endocrinology. 2021 Aug 1;162(8):bqab107. | doi: 10.1210/endocr/bqab107. Access the paper.
The Cholesterol Metabolite 27HC Increases Secretion of Extracellular Vesicles Which Promote Breast Cancer Progression.
Baek AE, Krawczynska N, Das Gupta A, Dvoretskiy SV, You S, Park J, Deng YH, Sorrells JE, Smith BP, Ma L, Nelson AT, McDowell HB, Sprenger A, Henn MA, Madak-Erdogan Z, Kong H, Boppart SA, Boppart MD, Nelson ER. | Endocrinology. 2021 Jul 1;162(7):bqab095. | doi: 10.1210/endocr/bqab095. PMID: 33959755; PMCID: PMC8197285. Access the paper.
Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer.
Williams MM, Spoelstra NS, Arnesen S, O'Neill KI, Christenson JL, Reese J, Torkko KC, Goodspeed A, Rosas E, Hanamura T, Sams SB, Li Z, Oesterreich S, Riggins RB, Jacobsen BM, Elias A, Gertz J, Richer JK. | Cancer Research. 2021 Feb 1;81(3):732-746. doi: 10.1158/0008-5472.CAN-20-1200. Access the paper.
Making an IMPACT on career development for early- and mid-career faculty.
Sikora MJ, Riggins RB, Madak-Erdogan Z. | Endocrinology. 2021 Jan 7;bqaa247. | doi: 10.1210/endocr/bqaa247. Access the paper.